Hansa Biopharma AB (LTS:0RC7) Growth Rank: 3 (As of Sep. 16, 2026) — 25% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RC7 Hansa Biopharma AB LTS:0RC7
35 GF Score
Price kr37.70
GF Value kr22.15
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Growth Rank?

Hansa Biopharma AB LTS:0RC7 -5.25% 35 Growth Rank is 3 as of Sep. 16, 2026, which is 25% below its 10-year median of 4.00. GuruFocus rates LTS:0RC7 with a GF Score™ of 35/100 and a GF Value™ of kr22.15 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Hansa Biopharma AB has the Growth Rank of 3.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Hansa Biopharma AB Growth Rank Related Terms

LTS:0RC7 vs VRTX, REGN, MRNA: Growth Rank Comparison

For the Biotechnology subindustry, Hansa Biopharma AB's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hansa Biopharma AB Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Growth Rank distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Growth Rank falls into.


LTS:0RC7
35GF Score
Hansa Biopharma AB LTS:0RC7
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 3 mean?
Hansa Biopharma AB (LTS:0RC7) has a Growth Rank of 3 as of Sep. 16, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Hansa Biopharma AB and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Hansa Biopharma AB's Growth Rank has ranged from 1.00 to 10.00.
Is Hansa Biopharma AB's Growth Rank too high?
Hansa Biopharma AB's current Growth Rank of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Hansa Biopharma AB has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Growth Rank compare to VRTX and REGN?
Hansa Biopharma AB's Growth Rank of 3 can be compared against companies in the Biotechnology industry. Historically, Hansa Biopharma AB's own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Growth Rank is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (LTS:0RC7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr22.15, compared to a current price of kr37.70 — trading 70.2% above its estimated fair value. The current Growth Rank is 3, which is 25% below median its 10-year median of 4.00. Hansa Biopharma AB's overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Hansa Biopharma AB (LTS:0RC7), the current Growth Rank is 3 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (LTS:0RC7) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr37.70 is trading 70.2% above its estimated GF Value™ of kr22.15. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for LTS:0RC7:

  • Growth Rank: 3 (25% below median its 10-year median of 4.00)
  • GF Value™: kr22.15 vs. price of kr37.70 (70.2% above fair value)
  • GF Score™: 35/100 with 5 warning signs

No single metric tells the full story. See the LTS:0RC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
35GF Score

Get the complete analysis for LTS:0RC7

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr37.70
Price
kr22.15
GF Value